15.08.2021, 1362 Zeichen

Valneva: Valneva’s total revenues were Euro 47.5 mn in the first half of 2021 compared to Euro 47.9 mn in the first half of 2020. Product sales declined by 22.4% to Euro 31.8 mn in the first half of 2021 compared to Euro 40.9 mn in the first half of 2020. Valneva recorded an operating loss of Euro 86.2 mn in the first half of 2021 compared to an operating loss of Euro 21.9 mn in the first half of 2020. EBITDA loss in the first half of 2021 was €80.1 million compared to an EBITDA loss of Euro 17.2 mn in the first half of 2020. In the first half of 2021, Valneva generated a net loss amounting to Euro 86.4 mn compared to a net loss of Euro 25.6 mn in the first half of 2020.  Thomas Lingelbach, Valneva’s Chief Executive Officer, commented, “Valneva is continuing to hit its major R&D objectives. We have just reported great results in the world’s first ever Phase 3 trial for a chikungunya vaccine alongside excellent progress for our unique COVID and Lyme disease programs. Our successful Nasdaq listing marked a significant strategic step for Valneva as we look to continue to build our Company. Our team has delivered phenomenally well this year already and I would like to thank them for their continued commitment and dedication.”
Valneva: weekly performance: -9.40%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (10/08/2021)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S24/09: Bernadette Händlhuber

Bildnachweis

Aktien auf dem Radar:UBM, Agrana, CA Immo, Austriacard Holdings AG, EuroTeleSites AG, Polytec Group, Frequentis, Rosgix, EVN, Uniqa, Österreichische Post, AT&S, Rosenbauer, Lenzing, Addiko Bank, Frauenthal, SBO, Verbund, BTV AG, Athos Immobilien, Oberbank AG Stamm, Amag, Flughafen Wien, CPI Europe AG, Semperit, Telekom Austria, Münchener Rück, RWE, Allianz, DAIMLER TRUCK HLD..., Fresenius Medical Care.

---